|
| Index | - | P/E | - | EPS (ttm) | -0.42 | Insider Own | 40.25% | Shs Outstand | 17.23M | Perf Week | -1.42% |
| Market Cap | 45.94M | Forward P/E | - | EPS next Y | -0.86 | Insider Trans | 33.26% | Shs Float | 6.48M | Perf Month | -16.59% |
| Income | -1.20M | PEG | - | EPS next Q | -0.23 | Inst Own | 19.70% | Short Float | 1.54% | Perf Quarter | -3.61% |
| Sales | - | P/S | - | EPS this Y | -15.90% | Inst Trans | -0.38% | Short Ratio | 0.94 | Perf Half Y | -40.99% |
| Book/sh | 10.56 | P/B | 0.33 | EPS next Y | 4.40% | ROA | -2.80% | Target Price | 14.50 | Perf Year | -67.72% |
| Cash/sh | 0.00 | P/C | - | EPS next 5Y | - | ROE | -3.10% | 52W Range | 3.29 - 15.10 | Perf YTD | -60.32% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -77.54% | Beta | - |
| Dividend % | - | Quick Ratio | 0.10 | Sales past 5Y | - | Gross Margin | - | 52W Low | 3.10% | ATR | 0.19 |
| Employees | 5 | Current Ratio | 0.10 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 31.16 | Volatility | 3.96% 4.83% |
| Optionable | Yes | Debt/Eq | 0.07 | EPS Q/Q | -336.80% | Profit Margin | - | Rel Volume | 0.08 | Prev Close | 3.47 |
| Shortable | Yes | LT Debt/Eq | 0.07 | Earnings | - | Payout | - | Avg Volume | 106.51K | Price | 3.39 |
| Recom | 2.00 | SMA20 | -10.87% | SMA50 | -13.99% | SMA200 | -37.55% | Volume | 1,024 | Change | -2.25% |
 | ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's disease, parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis; and RP1208 that has completed pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California. | ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite